Skip to main content
. 2018 Jan 17;13(1):e0189582. doi: 10.1371/journal.pone.0189582

Fig 3. Significant KEGG pathways and the genes involved.

Fig 3

Gene enrichment analysis showing KEGG pathways significantly enriched in bevacizumab resistant HT29 xenograft tumors and the genes involved in the pathways (the pathways are in order of their enrichment from left to right) (FDR <0.05, p-value <0.05).